Stock
Ownership of a fraction of a corporation and the right to claim a share of the corporation's assets and profits equal to the amount of stock owned
US listed securityListed on NASDAQ
US headquarteredHeadquartered in Chatham, New Jersey, United States
addFollow
Tonix Pharmaceuticals Holding Corp
$1.03
TNXP
After Hours:(arrow_upward0.97%)+$0.01
$1.04
Closed: Jan 22, 7:59:24 PM GMT-5 · USD · NASDAQ · Disclaimer
In the news
Financial performance
| (USD) | Q3 2020 | Year/year change |
|---|---|---|
Revenue | - | - |
Net income | -11.99M | arrow_downward-52.97% |
| Diluted EPS | -0.09 | arrow_upward98.42% |
| Net profit margin | - | - |
| Operating income | -12.00M | arrow_downward-52.06% |
| Net change in cash | 775.00K | arrow_upward136.45% |
| Cash on hand | 55.66M | arrow_upward455.25% |
| Cost of revenue | - | - |
About
Tonix Pharmaceuticals is a pharmaceutical company based in New York City that focuses on repurposed drugs for central nervous system conditions and as of 2020 was also pursuing a vaccine for COVID-19 and a biodefense project.
The company's predecessors were Tamandare Explorations Inc. which had been formed in 2007 as a mining wildcat vehicle focused on land in Nevada and the shares of which were traded over the counter, and L & L Technologies, LLC, which had been formed in 1996 by Seth Lederman and Donald Landry to repurpose drugs for CNS development. L&L had formed Janus Pharmaceuticals, Inc., which later became Vela Pharmaceuticals, Inc. to develop some of its inventions, and Vela returned those assets to L&L in 2006. L&L placed them in a subsidiary called Krele Pharmaceuticals, Inc., and that subsidiary and Tamandare Explorations Inc. performed a reverse merger in October 2011; the new entity was renamed Tonix Pharmaceuticals Holding Corp. and Lederman was named CEO. It was listed on the NASDAQ exchange in 2013 under the symbol TNXP. Wikipedia
Founded
2007
Headquarters
Website
Employees
16
Key stats
Previous close
The last closing price
$0.98
Day range
The difference between the high and low prices over the past day
$0.97 - $1.07
Year range
The difference between the high and low prices over the past 52 weeks
$0.39 - $2.46
Market cap
A valuation method that multiplies the price of a company's stock by the total number of outstanding shares.
272.72M USD
Volume
The average number of shares traded each day over the past 30 days
32.99M
P/E ratio
The ratio of current share price to trailing twelve month EPS that signals if the price is high or low compared to other stocks
-
Dividend yield
The ratio of annual dividend to current share price that estimates the dividend return of a stock
-
Primary exchange
Listed exchange for this security
NASDAQ
About
Tonix Pharmaceuticals is a pharmaceutical company based in New York City that focuses on repurposed drugs for central nervous system conditions and as of 2020 was also pursuing a vaccine for COVID-19 and a biodefense project.
The company's predecessors were Tamandare Explorations Inc. which had been formed in 2007 as a mining wildcat vehicle focused on land in Nevada and the shares of which were traded over the counter, and L & L Technologies, LLC, which had been formed in 1996 by Seth Lederman and Donald Landry to repurpose drugs for CNS development. L&L had formed Janus Pharmaceuticals, Inc., which later became Vela Pharmaceuticals, Inc. to develop some of its inventions, and Vela returned those assets to L&L in 2006. L&L placed them in a subsidiary called Krele Pharmaceuticals, Inc., and that subsidiary and Tamandare Explorations Inc. performed a reverse merger in October 2011; the new entity was renamed Tonix Pharmaceuticals Holding Corp. and Lederman was named CEO. It was listed on the NASDAQ exchange in 2013 under the symbol TNXP. Wikipedia
Founded
2007
Headquarters
Website
Employees
16
